Latest Ratios: P/E Ratio -21.3x · EV/EBITDA N/A · ROE -74.4%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $237M | $154M | $204M | $281M | $60M | $105M | $93M | $6M | $6M | $15M | $9M |
| Enterprise Value | $207M | $123M | $194M | $267M | $60M | $65M | $85M | $6M | $6M | $15M | $9M |
| P/E Ratio → | -21.35 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.22 | 0.79 | 0.96 | 1.84 | 0.50 | 1.13 | 2.50 | 0.48 | 0.76 | 2.96 | 1.75 |
| P/B Ratio | 9.57 | 6.65 | — | 50.50 | — | 4.05 | — | — | 7.73 | 24.01 | — |
| P/FCF | 37.05 | 24.01 | 34.12 | 3232.66 | — | — | — | 23.62 | — | — | — |
| P/OCF | 28.68 | 18.59 | 11.64 | 31.87 | — | — | — | 23.62 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.64 | 0.91 | 1.75 | 0.51 | 0.70 | 2.28 | 0.46 | 0.77 | 2.96 | 1.75 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 93.14 | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 19.26 | 32.46 | 3069.18 | — | — | — | 22.58 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.8% | 79.8% | 88.7% | 87.6% | 84.3% | 80.6% | 76.2% | 79.7% | 76.3% | 70.6% | 62.9% |
| Operating Margin | -4.0% | -4.0% | -7.6% | -9.5% | -36.5% | -58.5% | -155.0% | -23.2% | -24.7% | -21.1% | -22.4% |
| Net Profit Margin | -3.7% | -3.7% | -8.9% | -13.5% | -38.3% | -65.6% | -157.3% | -25.2% | -14.9% | -23.9% | -21.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.4% | -74.4% | -2483.1% | -370.0% | -491.9% | -487.2% | — | — | -172.0% | -923.7% | — |
| ROA | -9.9% | -9.9% | -28.8% | -49.0% | -120.5% | -192.3% | -696.1% | -103.5% | -64.0% | -117.4% | -178.9% |
| ROIC | — | — | — | — | — | — | — | — | -200.8% | -514.9% | — |
| ROCE | -37.4% | -37.4% | -89.9% | -161.1% | -406.3% | -408.8% | — | -646.1% | -200.9% | -817.7% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | — | 3.40 | — | 0.07 | — | — | 0.30 | 0.27 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 1.04 | — |
| Net Debt / Equity | — | -1.32 | — | -2.55 | — | -1.53 | — | — | 0.08 | 0.04 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.16 | — |
| Debt / FCF | — | -4.75 | -1.66 | -163.48 | — | — | — | -1.04 | — | — | — |
| Interest Coverage | -5.64 | -5.64 | -7.40 | -5.58 | -31.10 | -17.98 | -34.67 | -3.80 | -5.80 | -12.72 | -24.16 |
Net cash position: cash ($37M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | 1.25 | 0.81 | 1.22 | 0.36 | 1.97 | 0.89 | 0.69 | 1.35 | 1.97 | 0.69 |
| Quick Ratio | 1.18 | 1.18 | 0.76 | 1.15 | 0.24 | 1.90 | 0.80 | 0.45 | 0.49 | 0.87 | 0.55 |
| Cash Ratio | 0.88 | 0.88 | 0.58 | 0.95 | 0.13 | 1.81 | 0.66 | 0.28 | 0.15 | 0.22 | 0.16 |
| Asset Turnover | — | 2.76 | 2.93 | 2.61 | 4.64 | 1.86 | 2.78 | 3.62 | 3.18 | 4.00 | 6.63 |
| Inventory Turnover | 14.17 | 14.17 | 8.60 | 6.85 | 5.04 | 11.13 | 7.01 | 2.66 | 1.93 | 2.10 | 12.14 |
| Days Sales Outstanding | — | 17.50 | 14.12 | 12.63 | 8.69 | 3.85 | 9.77 | 2.85 | 4.34 | 9.26 | 31.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.4% | 2.0% | 1.5% | 1.1% | 5.2% | 0.8% | 1.4% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 2.7% | 4.2% | 2.9% | 0.0% | — | — | — | 4.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.9% |
| Total Shareholder Yield | 1.4% | 2.0% | 1.5% | 1.1% | 5.2% | 0.8% | 1.4% | 0.0% | 0.0% | 0.5% | 0.9% |
| Shares Outstanding | — | $45M | $41M | $34M | $31M | $27M | $14M | $10M | $9M | $9M | $7M |
High Customer Acquisition Costs
Based on current market data, LifeMD trades at a P/S ratio of 1.03, which appears to discount the company's hybrid SaaS and telehealth model relative to pure-play peers like Hims & Hers, suggesting the market remains skeptical of the firm's ability to achieve long-term operating profitability.
The valuation reflects a significant divergence from high-growth telehealth peers, likely due to the company's negative earnings and recent revenue contraction. Investors should monitor whether the market begins to assign a higher multiple to the WorkSimpli software segment, which provides a stable, high-margin cash flow buffer that is currently being overshadowed by the clinical segment's losses.
According to recent financial statements, LifeMD's cash conversion cycle remains deeply negative, reaching -210 days in 2026Q1, which indicates that the company relies heavily on collecting subscription revenue upfront to fund its ongoing clinical operations and marketing-heavy customer acquisition strategy.
While a negative CCC is often a hallmark of efficient subscription models, the extreme nature of this figure suggests a potential reliance on aggressive billing or deferred revenue recognition. The high DPO relative to DSO warrants further investigation into whether the company is stretching supplier payment terms to preserve liquidity during periods of top-line decline.
As reported in quarterly filings, the company's current ratio of 1.04 in 2026Q1 highlights a precarious liquidity position, leaving the firm with minimal margin for error should customer acquisition costs spike or if the software segment experiences a sudden increase in churn.
The proximity of the current ratio to unity suggests that LifeMD lacks the balance sheet cushion typically required for a company in a high-burn, growth-oriented phase. This tight liquidity profile necessitates disciplined capital allocation, as any unexpected operational shortfall could force the company to seek dilutive financing to maintain its clinical infrastructure.
Investors frequently misapply the P/E ratio to LifeMD, a metric that obscures the company's true earning power by failing to account for the heavy, non-recurring marketing investments required to scale its clinical subscriber base in a highly competitive digital healthcare market.
Because the company is currently prioritizing growth and market share over GAAP profitability, the P/E ratio provides a distorted view of its fundamental health. A more appropriate analytical framework would involve evaluating the LTV/CAC ratio or adjusted EBITDA, which better capture the underlying unit economics of the telehealth and SaaS segments.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LFMD stock.
LifeMD, Inc.'s current P/E ratio is -21.3x. This places it at the 50th percentile of its historical range.
LifeMD, Inc.'s return on equity (ROE) is -74.4%. The historical average is -298.4%.
Based on historical data, LifeMD, Inc. is trading at a P/E of -21.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
LifeMD, Inc.'s current dividend yield is 1.40%.
LifeMD, Inc. has 79.8% gross margin and -4.0% operating margin.